🇪🇺 SOGROYA in European Union

EMA authorised SOGROYA on 31 March 2021

Marketing authorisation

EMA — authorised 31 March 2021

  • Application: EMEA/H/C/005030
  • Marketing authorisation holder: Novo Nordisk A/S
  • Local brand name: Sogroya
  • Indication: Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).
  • Pathway: orphan
  • Status: approved

Read official source →

SOGROYA in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is SOGROYA approved in European Union?

Yes. EMA authorised it on 31 March 2021.

Who is the marketing authorisation holder for SOGROYA in European Union?

Novo Nordisk A/S holds the EU marketing authorisation.